The Communicator Awards, one of the most prestigious and competitive award programs honoring creative excellence for marketing and communication solutions, which draws over 6,000 entries from across the US and worldwide, named Viscira a Silver winner in three different categories for their interactive 3D animation entitled “Biogen Idec: Science Behind Alprolix.” The awards were given in the areas of video with animation, online video and interactive multimedia.
ALPROLIX™ is the first recombinant coagulation factor IX with a prolonged half-life, approved for the treatment of hemophilia B. The primary objective of the Science Behind Alprolix program is to educate healthcare professionals on the method by which the half-life of Alprolix is prolonged. This enables the product to work longer in the body and allows hemophilia patients to have fewer infusions.
This interactive MOA animation highlights the unique mode of action and efficacy of Alprolix. The video is highly cinematic, scientifically realistic and clinically sophisticated in tonality. It also incorporates Viscira's own proprietary Interactive Video Player (IVP) technology, a robust platform with streaming video capabilities, which enables delivery of various interactive features, including "hot spots" that allow for deep dives into some of the more complex scientific areas in the animation.
The Communicator Awards is in its 21st season and is the leading international awards program in marketing and communications. The Communicator Awards is sanctioned and judged by the Academy of Interactive & Visual Arts (AIVA). AIVA members include executives from organizations such as Conde Nast, Disney, Estee Lauder, Lockheed Martin, MTV Networks, and Yahoo!
Hagop (Kane) Kaneboughazian, Viscira's Vice President of Animation, commented on the award. “We are pleased this piece has been recognized in this way. This interactive video can help both healthcare professionals and hemophilia patients better understand how this important product works to make the most informed treatment decisions. As a company, we will continue to innovate using the most advanced 3D techniques to further raise the bar in medical animation.”